About 10-30% of patients with non-Hodgkin's lymphoma (NHL) intended to receive high-dose therapy are difficult to mobilise. Damage to the stem cell pool caused by previous chemotherapy may be an important factor in predicting progenitor cell mobilisation. We have analysed associations between chemotherapy score and efficiency of progenitor cell mobilisation in 120 consecutive NHL patients mobilised with intermediate-dose cyclophosphamide (4 g/m 2 ) plus G-CSF. The original chemotherapy scoring system proposed by Drake et al was applicable in only 27% of our patients and was not predictive for mobilisation outcome. Therefore we made an improved scoring system for previous chemotherapy by adding new drugs. Altogether, 111 patients (93%) could be scored. Our chemotherapy score showed an inverse correlation with the peak blood CD34 + count measured after the mobilisation (r ¼ À0.214, P ¼ 0.024) and with the number of CD34 + cells collected (r ¼ À0.234, P ¼ 0.02). However, in the receiver operating characteristics curve, no threshold value could be detected for chemotherapy score predicting mobilisation failure. Thus, both the original scoring system as well as our more widely applicable scoring system seem to be of limited value in predicting progenitor cell mobilisation in patients with NHL.
tion; non-Hodgkin's lymphoma Non-Hodgkin's lymphoma (NHL) is currently the leading indication for high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT).
1,2 Blood progenitor cells are now used for haemopoietic support in more than 90% of the patients. 2 Thus, efficient progenitor cell mobilisation is an essential part of HDT protocols.
Although progress has been made in various aspects of progenitor cell mobilisation in lymphoma patients, a significant proportion of patients intended to have HDT still fail to mobilise enough progenitor cells to proceed to HDT. Further, in a subgroup of the patients, the mobilisation is suboptimal: several apheresis procedures or even several mobilisation attempts are needed to reach the threshold values for an adequate graft. Previous chemotherapy is among the factors affecting the efficiency of progenitor cell mobilisation 3 . Drake et al 4 proposed a scoring system for previous chemotherapy predicting progenitor cell yield. Clark and Brammer 5 subsequently validated the scoring system. These series included a mixture of patient diagnoses including NHL, Hodgkin's lymphoma and multiple myeloma. Thus, the usefulness of this scoring system in patients with NHL remains to be elucidated.
We tried to evaluate the scoring system proposed by Drake et al 4 in 120 consecutive patients with NHL, who received an identical progenitor cell mobilisation with intermediate-dose cyclophosphamide (CY) (4 g/m 2 ) followed by G-CSF and were admitted to our centre for blood progenitor cell apheresis. Since only a minority of our patients could be adequately scored with the original system, we developed an improved system including several drugs that were missing from the original publication. Here, we present the application of this extended scoring system in patients with NHL to predict progenitor cell mobilisation.
Patients and methods

Patients
Between January 1995 and March 2002, 120 patients with NHL received progenitor cell mobilisation with CY 4 g/m 2 followed by G-CSF and came to our unit for progenitor cell aphaeresis. The patient characteristics are summarised in Table 1 .
Progenitor cell mobilisation and aphaeresis
All patients received CY 4 g/m 2 in a 90-min infusion on day 0 followed by MESNA. G-CSF was started 48 h later and continued until completion of aphaeresis or until realisation of a mobilisation failure. Aphereses were started based on blood CD34 + counts (B-CD34 + ). In general, aphereses were started when the B-CD34 + count exceeded 20 Â 10 6 /l, but in many patients thought to be poor mobilisers, aphereses were started with lower B-CD34 + counts (5-20 Â 10 6 /l) provided that they had concomitantly rising leucocyte counts (B-leuc 41 Â 10 9 /l). Aphereses were performed via central venous catheters in 490% of the patients with a COBE SPECTRA cell separator (COBE Laboratories Ltd., Gloucester, UK). A volume of 10-15 l of blood was processed within four hours and the number of CD34 + cells was counted after aphereses. In the case of CD34 + selection, at least 5 Â 10 6 /kg CD34 + cells were collected. Otherwise, the minimum target yield was 2 Â 10 6 /kg CD34 + cells. The minimum requirement to proceed to HDT was a collection of at least 1.5 Â 10 6 /kg CD34 + cells, which was also the criterion for successful progenitor cell mobilisation.
Assessment of progenitor cell mobilisation
Mobilisation efficiency was assessed as follows: 
Previous chemotherapy
All chemotherapy that the patients had received before the progenitor cell mobilisation was taken into account. The chemotherapy regimens used in these patients are summarised in Table 2 . The median number of regimens per patient was 2 (1-5); 66 patients (55%) had received two or more regimens. The median number of chemotherapy cycles was 8 (range 3-29); 41 patients (34%) had received at least 10 cycles.
An improved chemotherapy scoring system
When the chemotherapy scoring system proposed by Drake et al 4 was applied into this cohort of patients, some drawbacks of this system became readily apparent. Hence an improved scoring system was established. The basic principles were, however, adopted from Drake et al 4 including classification of chemotherapeutic agents with a proposed mechanism of action and known toxicity to progenitor cells. Grading of toxicity factor (TF) from 0 to 4 was retained in this modification. The chemotherapy scores for each cycle were calculated by summing the toxicity factors of individual drugs and multiplying this sum by the number of chemotherapy cycles given before progenitor cell mobilisation.
The following changes or modifications were made on the scoring system proposed by Drake et al:
4 Table 1 Characteristics of 120 patients with NHL who received progenitor cell mobilisation with a combination of CY 4 g/m 2 followed by G-CSF REAL=Revised European-American Classification of Lymphoid Neoplasms; 6 CR=complete remission; PR=partial remission; BM=bone marrow. Table 2 Chemotherapy preceding progenitor cell mobilisation in 120 patients with NHL. Only regimens given at least to two patients are included MIME=mitoguazon-ifosfamide-methotrexate-etoposide; M-BACOD=methotrexate-bleomycin-doxorubicin-cyclophosphamidevincristine-dexamethason; FND=fludarabine-mitoxantrone-dexamethasone; BAIOD=bleomycin-doxorubicin-ifosfamide-vincristine-dexamethason; IMVP-16=ifafamide-methotrexate-etoposide; ESHAP=etoposide-methylprednisolone-cytosine arabinoside-cisplatin; DICE=dexametha-sone-ifosfamide-cisplatin-etoposide; CNOP=cyclophosphamide-mitoxantrone-vincristine-prednisolone; MOPP-ABV=metchlorethamine-vincristineprocarbazine-prednisolone-doxorubicin-bleomycin-vinblastine. a Reiter et al. Chemotherapy scoring to predict mobilisation in NHL E Jantunen et al
(1) Methylprednisolone, a glucocorticoid, received TF 0 by analogy with other corticosteroids. (2) Chlorambucil, an alkylating agent, was given TF 3 when given continuously. A total of 1 month of oral therapy (usually 4-6 mg/day) was regarded as a cycle. (3) Ifosfamide, an alkylating agent, received TF 2 because it is closely related to CY and has been successfully used in combination regimens for treatment of relapse as well as for progenitor cell mobilisation in lymphoma patients. [9] [10] [11] (4) Methotrexate, an antimetabolite was given TF 1, because it is unlikely to cause permanent stem cell damage.
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(5) Cytosine arabinoside, an antimetabolite, was given TF 1, because it is unlikely to cause permanent progenitor cell damage 13 at least when used for short periods, which is the case in most lymphoma regimens. (6) Mitoxantrone, an anthracendione, was given TF 2, because it resembles anthracyclines in the mode of action. (7) Fludarabine, a nucleoside analogue, received TF 3.
Fludarabine-treated lymphoma patients have been found to be difficult to mobilise. 14 In some other series, previous use of fludarabine has been an important predictor of poor progenitor cell mobilisation. Limited data are available on the toxicity of this drug to the progenitor cell pool. Combination regimens, including mitoguazon, have been successfully used both for treatment of relapse as well as for progenitor cell mobilisation in lymphoma patients.
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(9) Dacarbazine, by analogy with procarbazine, received TF 3.
Examples in the application of the scoring system: CHOP ¼ 2+2+1+0 ¼ 5 points/cycle; CHOP 8 cycles ¼ 40 points; DHAP ¼ 0+1+2 ¼ 3 points/cycle; MIME 2+2+ 1+2 ¼ 7 points/cycle; MACOP-B (12 weeks) ¼ 36 points.
The improved chemotherapy scoring system is presented in Table 3 .
Statistical methods
All calculations were performed with an SPSS/PC statistical program (version 9.0, SPSS Inc., Chicago, IL, USA). The Mann-Whitney U-test was used to compare the chemotherapy scores in the patient groups with different mobilisation outcomes (failure, sufficient or excellent mobilisation). Spearman's correlation test was used to examine the association between the chemotherapy scores and the peak blood CD34 + counts as well as the number of CD34 + cells collected. Receiver operating characteristics (ROC) curve was used to evaluate the ability of chemotherapy score to predict mobilisation failure. A P-value o0.05 was considered as statistically significant. Blood progenitor cell mobilisation was successful in 101 patients (84%), whereas 19 patients experienced a mobilisation failure (collection of o1.5 Â 10 6 /kg CD34 + cells after a single mobilisation attempt). By applying the definitions for excellent mobilisation, 63 patients fulfilled this criterion.
The Drake scores and prediction of progenitor cell mobilisation
Application of the chemotherapy scoring system as proposed by Drake et al 4 was possible only in 32 patients (27%) of the whole patient cohort. The main reason for this was that many commonly used agents were missing from the original scoring system. Out of 32 patients who could be adequately scored, only three patients (9%) failed to mobilise, whereas nine patients (28%) fulfilled the criteria for sufficient and 20 patients (63%) fulfilled the criteria for excellent mobilisation, respectively. The Drake scores between the patients who failed to mobilise were somewhat higher than in those who achieved the minimum target yield after the mobilisation (medians 48 vs 35), but the difference did not reach statistical significance. No significant differences were observed in the Drake scores between those patients who had excellent mobilisation vs those with sufficient mobilisation either. No significant correlations between the Drake scores and the peak B-CD34 + counts or the apheresis yield were observed.
Application of the improved chemotherapy scoring system and prediction of progenitor cell mobilisation
Altogether, 19 out of 120 patients (16%) had received TF 3 or TF 4 drugs. In total 17 patients had received TF 3 drugs (fludarabine eight patients, chlorambucil seven patients, procarbazine one patient, and dacarbazine one patient). Only two patients (2%) had received TF 4 drugs Melphalan, carmustine, metchlorethamine, lomustine
Changes to the original scoring system proposed by Drake et al 4 are shown in capital letters. TF=toxicity factor. a oral continuous treatment (4-6 mg/day) for a month=1 cycle.
(metchlorethamine) prior to the progenitor cell mobilisation.
The improved scoring system could be applied in 111 patients (93%). Patients who could not be scored had received BFM or other ALL-like protocols as a part of their previous chemotherapy. The mobilisation efficiency observed in these 111 patients served as a test to the validity and potential usefulness of the improved chemotherapy scoring system.
Out of 111 patients in whom the improved scoring system could be fully applied, 14 patients (13%) failed to mobilise according to the criteria used, whereas 63 patients (58%) had an excellent mobilisation and in an additional 34 patients (30%), a sufficient graft was collected. The corresponding scores in these patients with different mobilisation characteristics are shown in Figure 1 . The median score was 44.5 (mean7SD 49724) for patients who failed mobilisation, 45 (mean7SD 49726) for those with a sufficient mobilisation and 36 (mean 7SD 45720) for those who showed an excellent mobilisation (P ¼ NS between the three groups). There was an inverse correlation between the chemotherapy scores and the peak B-CD34 + counts measured (r ¼ À0.214, P ¼ 0.024) as well as between the improved chemotherapy scores and CD34 + counts of the aphaeresis product (r ¼ À0.234, P ¼ 0.02). However, the ROC curve showed no threshold value for chemotherapy scores to predict mobilisation failure (Figure 2 ).
HDT and engraftment
Altogether, 101 patients proceeded to HDT, which consisted of either BEAC (n ¼ 65) or BEAM (n ¼ 36) supported by blood progenitor cells (n ¼ 98) or bone marrow cells (n ¼ 3) followed by G-CSF. Three patients were not evaluable for engraftment due to early death. All other patients engrafted. The median times to reach neutrophils 40.5 Â 10 9 /l and unsupported platelets 420 Â 10 9 /l were 10 and 12 days after the progenitor cell infusion, respectively.
Discussion
Previous chemotherapy has an important influence on the success of progenitor cell mobilisation in patients with haematological malignancies. 3, 4, [16] [17] [18] Most studies have included patients with heterogeneous diagnoses, previous therapy and mobilisation regimens. Drake et al 4 proposed a scoring system for previous chemotherapy predicting mobilisation efficiency in a patient population consisting mostly of NHL, Hodgkin's lymphoma and multiple myeloma. We aimed to test whether this scoring system could be useful in patients with NHL mobilised with intermediate-dose CY plus G-CSF.
The scoring system of Drake could be used only in a minority of our patients due to the fact that many commonly used drugs were missing from the original scoring system. In addition, only 2% of our patients had received TF 4 drugs and none of them had received melphalan or carmustine, which are well-known stem cell toxins. [19] [20] Application of the Drake score in our patient population was not predictive for the success of progenitor cell mobilisation. Lack of TF 4 drugs in the previous therapy of our patients is the most apparent explanation for the weak correlation of the chemotherapy score and efficacy of progenitor cell mobilisation observed.
As the original scoring system was applicable only in 27% of our patients, an improved chemotherapy scoring system was built. This developed scoring system was applicable in 93% of our patients. Unfortunately, the improved scoring system was not much more helpful in predicting adequate progenitor cell mobilisation than the original system. The only clear advantage of our scoring system when compared to the Drake system was that it is more wide applicable in patients with NHL. Although previous chemotherapy is apparently an important factor with regard to the quality and quantity of progenitor cell pool and hence predicting progenitor cell mobilisation capacity in patients with NHL, its influence is still difficult to quantitate in a clinically useful way. Many other as yet incompletely defined factors may have important roles in terms of adequate stem cell mobilisation. In addition, there may be important interindividual variation, which has also been observed in healthy stem cell donors. 21, 22 The main reason for the failure to predict mobilisation capacity on the basis of scoring of previous chemotherapy is, however, that limited information is available on the relative as well as absolute toxicity of various drugs on the progenitor cell pool. This is especially true when several drugs with variable modes of action are used concomitantly or sequentially. Therefore, any scoring system is arbitrary and at best has only some reflections of the reality.
To conclude, both the chemotherapy scoring system proposed by Drake et al 4 as well as the present improved scoring system have a limited capacity to predict progenitor cell mobilisation in patients with NHL. Until more information is available, it is advisable to avoid prolonged treatment with the most toxic drugs in patients intended for progenitor cell mobilisation and also limit the use of less toxic drugs. However, the decisions should be individualised, taking into account the clinical characteristics of the patients as well as the need for effective in vivo purging before progenitor cell mobilisation.
